Compugen CGEN · USD

Its shares trade under the ticker CGEN. It has been listed since 1 August 2000. In the fiscal year to 31 December 2025, it reported revenue of $72.8m and net income of $35.3m. At that date it held total assets of $156.9m and shareholders' equity of $102.7m.

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Anat Cohen-DayagExecutive Chairman of the Board, since 2002$1.3m
• Mr. Eran OphirPresident, Chief Executive Officer, Director, since 2020
• Mr. David SilbermanChief Financial Officer
• Dr. Oliver FroescheisSenior Vice President, Corporate and Business Development$666,349
• Dr. Zurit LevineSenior Vice President, Technology Innovation, since 2018$478,738
• Dr. Yaron TurpazSenior Vice President, Senior Advisor, Computational Discovery
• Ms. Michelle MahlerChief Medical Officer
• Mr. Gilead HalevyIndependent Director
• Dr. Michele HolcombIndependent Director
• Dr. Kinneret Livnat SavitskyIndependent Director, since 2000
• Mr. Eran PerryIndependent Director
• Mr. Sanford ZweifachIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.